|
 |
|
Penny's strong scientific background in the life sciences has led to her specialisation in advising clients in the bio pharma sector. She represents clients before the UK patent courts and has a wealth of experience in co-ordinating multi-jurisdictional patent litigation. She has represented clients in European Patent Office opposition and appeal proceedings. Penny has also represented clients in technology contract disputes before the UK courts and in arbitration proceedings and is a qualified mediator.
Penny also counsels on patent litigation strategy, including pharmaceutical lifecycle management, and is experienced in providing freedom to operate and due diligence advice.
Prior to founding Powell Gilbert, Penny was a partner at Bristows. She is a member of the Editorial Board of BioScience Law Review and frequently lectures on aspects of IP law affecting the life sciences sector. She is a member of AIPPI and a tutor on the Bristol University Diploma in Intellectual Property Law and Practice course.
Leading life sciences IP specialist with broad expertise, but best noted for multi-jurisdictional patent litigation and strategising for drug and biotech clients. Strong science background.
PLC Which Lawyer?
A dominant force in the biopharma sector. Recognised for her "brilliance in all things technical".
Chambers & Partners
Excellent reputation and strong track record particularly for patent litigation.
Legal 500
|
|
Contact details
DDI +44 (0)20 3170 8422
E penny.gilbert@powellgilbert.com
Qualifications
1991 Solicitor
2004 Mediator
2005 Solicitor Advocate
Education
MA (Biochemistry), Oxford University; DPhil (Molecular Biology), Oxford University
Diploma in Intellectual Property Law and Practice, Bristol University
Cases include
• Genentech v Wellcome (tPA)
• Genentech v Eli Lilly (HGH)
• Chiron v Murex & others (HCV)
• Chiron v Evans Medical & others (pertussis antigens)
• Quadrant v Roser (protein stabilisation)
• Inhale v Quadrant (protein stabilisation)
• Pharmacia v Merck (COX 2 inhibitors)
• Oxford Gene Technology v Affymetrix (DNA microarrays)
• Roche v Chiron (Fuzeon; Herceptin)
• Eli Lilly v Human Genome Sciences (Neutrokine alpha)
• Sandoz v Napp (controlled release opioid)
• Ratiopharm v Napp (controlled release opioid)
|
|